Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.6.0.2
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 01, 2012
USD ($)
Oct. 10, 2001
USD ($)
shares
Dec. 31, 2015
USD ($)
Nov. 30, 2015
USD ($)
Nov. 30, 2016
USD ($)
CompensationPlan
Segments
Agreement
Deliverables
Nov. 30, 2015
USD ($)
shares
Aug. 31, 2016
USD ($)
Schedule of Available-for-sale Securities [Line Items]              
Number of reportable segment | Segments         2    
Concentration risk related to supplier         Company depends on one supplier for the source of its collection kits    
Number of deliverables for revenue recognized | Deliverables         2    
Period of doubtful for accounts receivable due from client         21 years    
Contracted storage periods option two         21 years    
Contracted storage periods option one         1 year    
Contracted storage periods option three         Lifetime    
Deferred revenue recognition period         12 months    
Number of licensing agreement made by entity | Agreement         12    
Number of license agreement | Agreement         2    
Cash required to be deposited in bank for issuance of letter of credit       $ 200,000   $ 200,000  
Certificate of deposit with a principal balance       200,000 $ 204,000 200,000  
Impairment on long lived assets         0 0  
Goodwill impairment charge         $ 111,392   $ 1,666,430
Equity method investment, impairment loss           684,000  
Minimum percentage probability of realized tax benefit on settlement         50.00%    
Provisions for interest or penalties related to uncertain tax positions         $ 0 0  
Uncertain tax provisions       0 0 0  
Advertising cost included in selling, general and administrative expenses         1,186,000 756,000  
Unrealized holding gain (losses), trading securities         (17,000) (1,600)  
Unrealized gain (losses) on marketable securities, net of tax         (135,524) 169,932  
Payment warranty     $ 50,000        
Increased payment warranty $ 75,000            
Additional payment warranty $ 10,000            
Reserves recorded under programs       $ 17,000 $ 17,000 17,000  
Number of employee stock based compensation plan | CompensationPlan         2    
Stock-based option compensation expense         $ 1,772,000 $ 603,000  
Employee Stock Incentive Plan [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Number of outstanding options excluded from computation of diluted earnings per share | shares           225,000  
Other Income and Expense [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Realized gains on disposition of available for sale securities           $ 24,000  
Realized loss on disposition of available for sale securities         $ 0    
Accounts Receivable [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Period of doubtful for accounts receivable due from client         30 days    
PrepaCyte CB [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Goodwill impairment charge         $ 1,777,822    
Saneron [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Ownership interest       33.00% 33.00% 33.00%  
Equity method investment, impairment loss       $ 684,000      
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Non-Controlling interest after merger   43.42%          
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares   260,000          
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary   $ 1,924,000          
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]              
Schedule of Available-for-sale Securities [Line Items]              
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares   195,000          
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary   $ 3,900